Cargando…
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
AIMS: To determine the incidence of hyperkalaemia in patients with heart failure with reduced ejection fraction (HFrEF) during up‐titration of guideline‐directed medical therapy (GDMT) in real‐world settings. METHODS: A retrospective review of medical records of all patients hospitalized for newly o...
Autores principales: | Henrysson, Josefin, Thunström, Erik, Chen, Xiaojing, Fu, Michael, Basic, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871699/ https://www.ncbi.nlm.nih.gov/pubmed/36161782 http://dx.doi.org/10.1002/ehf2.14137 |
Ejemplares similares
-
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
por: Trevisan, Marco, et al.
Publicado: (2018) -
Treatment response in recent‐onset heart failure with reduced ejection fraction: non‐ischaemic vs. ischaemic aetiology
por: Silverdal, Jonas, et al.
Publicado: (2022) -
Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021) -
Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020) -
Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
por: Jadhav, Uday, et al.
Publicado: (2023)